Pediatric Anaphylaxis: Recognition, IM Epinephrine Dosing, and Discharge Planning
Bedside framework for recognizing pediatric anaphylaxis using NIAID/EAACI criteria, delivering weight-based IM epinephrine without delay, managing biphasic reactions, prescribing auto-injectors, and applying the LEAP-era food allergy framework.
Executive Summary
Pediatric anaphylaxis is a rapidly evolving, IgE-mediated systemic hypersensitivity reaction that is under-recognized, under-treated with epinephrine, and over-treated with antihistamines and steroids. Diagnosis uses NIAID/EAACI 2020 criteria: any acute illness involving skin/mucosa plus respiratory or cardiovascular compromise, or two organ systems after a likely allergen exposure, or hypotension after a known allergen. The single life-saving intervention is intramuscular epinephrine 0.01 mg/kg of the 1 mg/mL (1:1000) solution into the anterolateral thigh, with a maximum single dose of 0.5 mg, repeatable every 5–15 minutes. Auto-injector dosing follows weight bands: 0.15 mg for 7.5–25 kg (0.1 mg for 7.5 to <15 kg as an alternative where available, per the Auvi-Q label) and 0.3 mg for ≥25 kg; below 7.5 kg no auto-injector is labeled, so draw up 0.01 mg/kg from 1 mg/mL. Adjunctive therapies (H1 antihistamines like cetirizine 0.25 mg/kg, H2 blockers like famotidine, corticosteroids, bronchodilators, IV fluids) treat residual symptoms but never substitute for epinephrine. Biphasic reactions occur in up to 20% of pediatric cases — observe asymptomatic patients 4–6 hours after a single uncomplicated dose, longer for severe presentations. Discharge requires two auto-injectors, a written anaphylaxis action plan, allergy referral, and family education. The LEAP and EAT trials transformed prevention: early introduction of peanut, egg, and other allergens in high-risk infants between 4–6 months reduces food allergy development by 70–80%.
S1. Pathophysiology and Recognition
Anaphylaxis is a clinical diagnosis. In children, the classic IgE-mediated mechanism dominates: allergen exposure cross-links IgE bound to FcεRI receptors on mast cells and basophils, triggering degranulation with release of histamine, tryptase, leukotrienes, prostaglandins, platelet-activating factor, cytokines, and chemokines within minutes. The result is multi-system smooth muscle contraction, vasodilation, increased vascular permeability, and mucus production, producing the characteristic combination of urticaria, angioedema, bronchospasm, hypotension, and gastrointestinal symptoms.
NIAID/EAACI 2020 Diagnostic Criteria
Anaphylaxis is highly likely when any one of the following three criteria is met:
| Criterion | Required Features |
|---|---|
| Criterion 1 (most common) | Acute onset (minutes to hours) of illness with involvement of skin, mucosal tissue, or both (urticaria, pruritus, flushing, swollen lips/tongue/uvula) AND at least one of: (a) respiratory compromise (dyspnea, wheeze, stridor, hypoxemia), (b) reduced BP or end-organ dysfunction (hypotonia, syncope, incontinence) |
| Criterion 2 | Two or more of the following occurring rapidly after exposure to a likely allergen: (a) skin/mucosal involvement, (b) respiratory compromise, (c) reduced BP or end-organ dysfunction, (d) persistent GI symptoms (crampy pain, vomiting) |
| Criterion 3 | Reduced BP after exposure to a known allergen: pediatric hypotension defined as systolic BP <70 mmHg (1 mo–1 y), <70 + 2×age (1–10 y), <90 mmHg (11–17 y), or >30% drop from baseline |
Pediatric Pitfall: Skin Findings May Be Absent
Skin manifestations are present in 80–90% of cases — but their absence does not rule out anaphylaxis. Up to 10–20% of fatal cases have no skin findings, especially in young children, infants on beta-blockers, or rapidly progressing reactions. Trust respiratory or cardiovascular signs even without urticaria, particularly after a known or likely exposure.
Symptom Recognition by Organ System
| System | Common in Children | Severe / Red Flag |
|---|---|---|
| Skin / Mucosal (80–90%) | Urticaria, pruritus, flushing, lip/tongue/face swelling, conjunctival injection | Generalized urticaria with angioedema; periorbital swelling progressing to airway involvement |
| Respiratory (60–70%) | Cough, wheeze, dyspnea, hoarseness, throat tightness, rhinorrhea | Stridor, severe wheeze, cyanosis, SpO&sub2; <92%, retractions, silent chest, voice change |
| Cardiovascular (10–30%) | Tachycardia, dizziness, pallor, weak pulse, syncope | Hypotension, bradycardia (late, ominous), shock, cardiac arrest |
| Gastrointestinal (30–45%) | Crampy abdominal pain, nausea, vomiting, diarrhea | Persistent severe vomiting; GI symptoms in food-triggered cases often herald systemic progression |
| Neurologic | Anxiety, “feeling of impending doom”, irritability (preverbal child) | Confusion, lethargy, seizure, loss of consciousness |
Time Course of Anaphylaxis
Figure 1. Anaphylaxis time course — initial reaction peaks within 30 minutes, with possible biphasic recurrence 4–12 hours after symptoms resolve.
S2. Acute Management: Epinephrine First
The single most important action in anaphylaxis is immediate intramuscular epinephrine. Delays in epinephrine administration are the strongest predictor of fatal outcomes. Antihistamines, steroids, and bronchodilators are adjuncts only.
Epinephrine: Dose, Route, Concentration
| Parameter | Specification |
|---|---|
| Dose | 0.01 mg/kg IM (max single dose 0.5 mg in children, 0.5 mg in adults) |
| Concentration | 1 mg/mL (1:1000) — NOT the 0.1 mg/mL (1:10,000) used for cardiac arrest |
| Site | Anterolateral thigh (vastus lateralis) — fastest absorption; avoid deltoid in children |
| Repeat | Every 5–15 minutes if no response or symptom progression; up to 3 doses before considering IV infusion |
| IV indication | Persistent hypotension after 2–3 IM doses + IV fluids: epinephrine infusion 0.05–0.1 mcg/kg/min (titrate) |
Volume to Draw Up (1:1000 Solution)
| Weight (kg) | Dose (mg) | Volume of 1 mg/mL (mL) | Auto-injector device |
|---|---|---|---|
| 5 | 0.05 | 0.05 mL | Draw up (no auto-injector labeled below 7.5 kg) |
| 10 | 0.10 | 0.10 mL | 0.15 mg device |
| 15 | 0.15 | 0.15 mL | 0.15 mg device |
| 20 | 0.20 | 0.20 mL | 0.15 mg device (use 0.3 if >25 kg) |
| 25 | 0.25 | 0.25 mL | 0.3 mg device |
| 30 | 0.30 | 0.30 mL | 0.3 mg device |
| 40 | 0.40 | 0.40 mL | 0.3 mg device |
| ≥50 | 0.50 (max) | 0.50 mL | 0.3 mg or 0.5 mg device |
Concurrent Resuscitation (Epinephrine in Parallel, Not in Series)
Adjunctive Therapies (Never First-Line)
| Drug | Pediatric Dose | Role |
|---|---|---|
| Cetirizine (H1) | 0.25 mg/kg PO/IV (max 10 mg) | Relieves urticaria/itching only; preferred over diphenhydramine (less sedation, faster onset, IV form available) |
| Diphenhydramine (H1) | 1 mg/kg IV/IM/PO (max 50 mg) | Older H1; sedation can mask CNS deterioration; often given but not preferred |
| Famotidine (H2) | 0.25 mg/kg IV (max 20 mg) | Adjunct to H1 for urticaria/flushing; modest evidence |
| Methylprednisolone | 1–2 mg/kg IV (max 125 mg) | Often given but recent evidence (2020 Cochrane, 2024 cohort studies) shows no proven prevention of biphasic reactions; use selectively for severe asthma component |
| Albuterol nebulized | 2.5 mg neb (5 mg if >30 kg) | For persistent bronchospasm after epinephrine |
| Glucagon IV | 20–30 mcg/kg IV bolus, then 5–15 mcg/min infusion | If on beta-blocker with refractory shock |
| Vasopressors (norepi) | 0.05–0.5 mcg/kg/min IV | Refractory hypotension after IV fluids + repeated epinephrine; use with PICU support |
S3. Biphasic Reactions and Observation
A biphasic anaphylactic reaction is a recurrence of symptoms 1–72 hours (typically 4–12 hours) after the initial episode resolves, without re-exposure to the trigger. Reported pediatric incidence ranges from 5% to 20% depending on definition; clinically significant biphasic reactions requiring additional epinephrine occur in roughly 5%.
Predictors of Biphasic Reaction
- Severity of initial reaction (hypotension, hypoxia, throat involvement)
- Delayed epinephrine administration (each 30-minute delay increases biphasic risk)
- Need for >1 dose of epinephrine
- Wide pulse pressure or tachycardia at discharge
- Unknown trigger (cannot avoid re-exposure)
- History of biphasic reaction
Observation Periods (AAP / EAACI Consensus)
| Clinical scenario | Recommended observation |
|---|---|
| Mild–moderate reaction, single epinephrine dose, complete resolution, low-risk trigger known | 4–6 hours post symptom resolution, then discharge with action plan |
| Required >1 epinephrine dose, severe respiratory or CV symptoms, or unknown trigger | 12–24 hours observation; consider admission |
| Hypotension requiring fluids/vasopressors, intubation, refractory bronchospasm | PICU admission; minimum 24-hour observation post-resolution |
| History of biphasic reaction or known severe asthma | Extend observation to at least 12–24 hours |
What to Watch For During Observation
- Recurrence of skin findings (urticaria, flushing, lip swelling)
- Respiratory deterioration (wheeze, stridor, increased work of breathing)
- Cardiovascular changes (tachycardia, hypotension, syncope)
- GI symptoms (vomiting, abdominal pain)
- Vital signs every 15–30 minutes initially, then hourly if stable
S4. Common Triggers and Mimics
Pediatric Triggers by Age and Frequency
| Age group | Most common triggers | Notes |
|---|---|---|
| Infants (<1 y) | Cow’s milk, egg, peanut, soy, wheat | Often presents as feeding-associated reactions; consider FPIES as a differential (delayed, profuse vomiting) |
| Toddlers / preschool (1–5 y) | Peanut, tree nuts, egg, milk, sesame | Sesame added as 9th major US allergen (FASTER Act 2021); look for “vegan” or unlabeled bakery items |
| School age (6–12 y) | Peanut, tree nuts, fish, shellfish, sesame | Peanut and tree nut allergies often persist into adulthood |
| Adolescents (13–18 y) | Peanut, tree nuts, shellfish, fish, sesame, exercise-induced (food-dependent) | High-risk group for fatal anaphylaxis (delayed self-treatment, asthma comorbidity, restaurant exposures, alcohol disinhibition) |
| All ages | Hymenoptera stings, drugs (beta-lactams, NSAIDs), latex, vaccines (rare) | Drug-induced anaphylaxis often biphasic; latex high-risk in spina bifida patients |
The “Top 9” Pediatric Food Allergens
Peanut, tree nuts, milk, egg, wheat, soy, fish, shellfish, and sesame account for >90% of pediatric food anaphylaxis. Sesame was added to the US labeling law in January 2023 (FASTER Act).
Differential Diagnosis
| Mimic | Key distinguishing features |
|---|---|
| Vasovagal syncope | Bradycardia (not tachycardia), pallor without urticaria, prompt recovery when supine |
| Acute asthma exacerbation | Wheezing without urticaria/angioedema, no clear allergen exposure (though severe asthma can coexist with anaphylaxis) |
| Foreign body aspiration | Sudden onset, choking, focal wheeze/stridor, no skin findings; consider in toddlers |
| Panic attack / hyperventilation | Paresthesias, tetany, normal exam findings, no urticaria |
| Vocal cord dysfunction | Inspiratory stridor without bronchospasm; flat flow-volume loop on inspiratory limb |
| Scombroid poisoning | Mimics anaphylaxis (flushing, urticaria, GI), but caused by histamine in spoiled fish (tuna, mahi-mahi); responds to antihistamines |
| FPIES (food protein–induced enterocolitis) | Profuse vomiting + lethargy 1–4h after food; no urticaria, no respiratory distress, often cow’s milk/soy/oats/rice in infants |
| Mast cell activation syndrome (MCAS) | Recurrent multi-system symptoms with elevated tryptase or other mediators; consider in repeated unexplained anaphylaxis |
| Idiopathic anaphylaxis | No identifiable trigger after thorough workup; treat episodes the same; consider prophylactic therapy if recurrent |
Tryptase Testing (When Diagnosis Unclear)
Serum tryptase peaks 1–2 hours after symptom onset and returns to baseline by 6–8 hours. A level >11.4 ng/mL (or >1.2 × baseline + 2 ng/mL) supports mast cell activation. Useful when the diagnosis is unclear, when anaphylaxis is fatal/peri-arrest, or when MCAS is suspected. Order acute (within 4 hours) and a baseline level >24 hours after recovery.
S5. Discharge Planning, Action Plan, Auto-Injector Prescription
Discharge after anaphylaxis is a critical teaching opportunity that can prevent future fatalities. Every patient with anaphylaxis should leave with five things: epinephrine prescription, demonstration of use, written action plan, allergy referral, and clear “when to return” criteria.
Auto-Injector Prescription
| Patient weight | Auto-injector dose | Devices available |
|---|---|---|
| <7.5 kg | 0.01 mg/kg drawn up | No auto-injector labeled below 7.5 kg; use 1 mg/mL |
| 7.5 to <15 kg (alternative) | 0.1 mg | Auvi-Q 0.1 mg (US, labeled 7.5 to <15 kg); not all countries |
| 7.5–25 kg | 0.15 mg | EpiPen Jr, Auvi-Q 0.15, Adrenaclick Jr |
| ≥25 kg | 0.3 mg | EpiPen, Auvi-Q 0.3, Adrenaclick |
| ≥50 kg (some regions) | 0.5 mg | Emerade 0.5 mg (UK/Europe) |
Anaphylaxis Action Plan (Written, Pictorial)
Provide a written action plan customized to the child, signed by a clinician, copies for parents, school nurse, and caregivers. Standard templates: AAAAI, Food Allergy Research & Education (FARE), Anaphylaxis Canada. Plan should include:
- Child’s name, photo, weight, allergens, asthma comorbidity
- Mild symptom list with H1 antihistamine dose (cetirizine)
- Severe symptom list with epinephrine instruction (auto-injector dose, anterolateral thigh, through clothing)
- “After epinephrine: call 911” instruction, position supine with legs raised
- Auto-injector device images (EpiPen, Auvi-Q) with use steps
- Emergency contacts and prescribing physician info
Discharge Education Checklist
- Demonstrate auto-injector use on a trainer device; have parent/child return-demonstrate
- Review trigger identification and avoidance (food labels, restaurant strategies, “may contain” warnings)
- Always carry two auto-injectors in original packaging at body temperature (extreme heat/cold inactivates)
- Check expiration date — set calendar reminder; epinephrine expires 12–18 months from manufacture
- Use auto-injector even if uncertain — risk of withholding far exceeds risk of unnecessary dose
- Always call 911 after epinephrine use for transport and observation, even if feeling better
- Wear medical ID bracelet (MedicAlert)
- Allergy follow-up within 4 weeks for confirmatory testing and management plan
- School notification: action plan to nurse, teacher, cafeteria; some schools require physician-signed forms
S6. Long-term Follow-up and the LEAP/EAT Era
The 2015 LEAP trial transformed pediatric food allergy prevention by demonstrating that early peanut introduction in high-risk infants reduces peanut allergy by ~80% compared with avoidance. The 2016 EAT trial extended this concept to multiple allergens. NIAID 2017 and AAP 2019 guidelines now recommend early introduction across the spectrum of risk.
LEAP Trial Summary
- 640 high-risk infants (severe eczema, egg allergy, or both) age 4–11 months randomized to early peanut introduction or strict avoidance until age 5
- Early introduction group: peanut allergy at age 5 was 1.9% (avoidance group: 13.7%), an 81% relative risk reduction
- LEAP-On: tolerance persisted after 12-month avoidance period in early-introduction group
NIAID 2017 Peanut Introduction Guidance
| Risk group | Recommendation | Pre-introduction testing |
|---|---|---|
| High risk: severe eczema and/or egg allergy | Introduce age-appropriate peanut foods at 4–6 months | Strongly consider peanut-specific IgE or skin prick test before; if SPT 0–2 mm or IgE <0.35 introduce at home; if larger, supervised feeding with allergist |
| Moderate risk: mild–moderate eczema | Introduce around 6 months as part of solid foods | Testing not required |
| Low risk: no eczema, no other food allergy | Introduce at age-appropriate time (around 6 months) with family preferences | No testing |
How to Introduce Peanut Safely at Home
- Wait until baby has tolerated other solid foods (often rice cereal, pureed vegetables/fruits)
- Forms suitable for infants: smooth peanut butter thinned with warm water/breast milk/formula, peanut puff snacks (e.g., Bamba), peanut powder mixed into purees
- Never give whole peanuts or chunks of peanut butter (choking hazard until age 4)
- Start with small amount (¼ teaspoon) and observe 10–15 minutes; increase if no reaction
- Continue regular peanut consumption ≥2–3 times/week
- If reaction: stop, give H1 if mild urticaria; epinephrine if any respiratory or systemic features
Other Foods (EAT Trial Framework)
The EAT trial showed early introduction (age 3 months) of multiple allergens (peanut, egg, milk, sesame, fish, wheat) into the breastfed infant diet reduced food allergy by ~67% in the per-protocol analysis. AAP 2019 supports introduction of allergenic foods around 4–6 months alongside other complementary foods. Egg should be cooked thoroughly (no raw or undercooked egg). Sesame products (tahini, hummus) introduced as smooth pastes mixed with foods.
Long-term Allergy Outcomes by Trigger
| Allergen | Resolution rate by school age |
|---|---|
| Cow’s milk | ~80% by age 16 |
| Egg | ~70% by age 16 |
| Wheat | ~65% by age 12 |
| Soy | ~65% by age 10 |
| Peanut | ~20% (most persist into adulthood) |
| Tree nuts | ~10% (most persist) |
| Fish / shellfish | Most persist into adulthood |
Oral Immunotherapy (OIT) for Peanut Allergy
Palforzia (peanut oral immunotherapy) was FDA-approved in 2020 for ages 4–17 with confirmed peanut allergy. Achieves “bite-proof” protection (typically tolerating 600 mg cumulative peanut protein, ~2 peanuts) in 67% by 6–12 months. Side effects: mild GI symptoms, eosinophilic esophagitis (rare), need for daily dosing. Does not “cure” allergy — patients must continue daily maintenance and carry epinephrine.
S7. Pearls, Pitfalls, and FAQ
Frequently Asked Questions
Practice Insights: Lessons from Pediatric Anaphylaxis in ED and Allergy Clinic
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Waiting for wheeze or hypotension before giving epinephrine misreads an anaphylaxis diagnosis that was already made at the door, which explains why the failures in this disease are almost never about diagnosis at the bedside — they are about epinephrine delay before arrival, the second-dose hesitation in the emergency department, the discharge planning that omits the spare auto-injector, and the LEAP-era introduction window that primary care still treats as “delay until age 3.” In experienced practice the four patterns experienced clinicians track most carefully are the antihistamine-first reflex that delays epinephrine, the underdosing or wrong-site administration that compromises absorption, the biphasic-reaction observation window that has shifted shorter for mild cases, and the early-introduction conversation that prevents future anaphylaxis entirely in high-risk infants.
1. Epinephrine First, Adjuncts Second
The single most common preventable bad outcome in pediatric anaphylaxis seasoned clinicians see is the antihistamine-first or “let’s see if it gets worse” reflex. In experienced practice the threshold to give intramuscular epinephrine is the presence of any two body-system involvement — skin plus respiratory, respiratory plus cardiovascular, or any known allergen exposure with hypotension or airway involvement — without waiting for the full diagnostic certainty. Diphenhydramine is an adjunct for itch and urticaria, not a treatment for anaphylaxis. Experienced practitioners would rather give a dose of epinephrine to a child whose final diagnosis turns out to be severe urticaria than withhold it from one whose anaphylaxis progresses while they temporize.
2. Vastus Lateralis, Not Deltoid — and Not Subcutaneous
The under-recognized administration error is the deltoid intramuscular shot or the older subcutaneous route. In practice the mid-anterolateral thigh (vastus lateralis muscle) is the site of every IM epinephrine dose, and experienced clinicians teach it explicitly to school nurses and parents at every auto-injector visit. The vastus has the highest perfusion among accessible IM sites and the fastest peak serum epinephrine; the deltoid is meaningfully slower and the subcutaneous route is the slowest of all. Auto-injectors are designed to be activated through clothing, and field administration should never be delayed for clothing removal.
3. The Second Dose Threshold Is Real
Roughly 40% of pediatric anaphylaxis cases need at least two doses of epinephrine — a number clinicians have learned to internalize and pre-empt rather than be surprised by. In practice if there is any persistent or worsening respiratory symptom, any continued hypotension after intravenous fluid bolus, or any progression toward cardiovascular collapse at the 5- to 15-minute reassessment, the second IM dose is given without further deliberation. The single-dose mindset is, in experienced hands, the most common contributor to bad outcomes in this disease.
4. Introduce Peanut Early in High-Risk Infants — LEAP Reshaped This
The LEAP trial reshaped allergy prevention so dramatically that the “delay introduction to age 3” guidance seasoned clinicians trained under is now actively harmful. In experienced practice every infant with severe eczema or established egg allergy receives a structured peanut-introduction conversation at the 4- to 6-month well-child visit; the highest-risk subgroup (both eczema and egg allergy) earns a skin prick test, and home introduction is offered if the wheal is under 3 mm, supervised in-clinic challenge if 3–7 mm, and avoidance plus ongoing surveillance if greater than 7 mm. The EAT trial extended this paradigm to other allergens, and the 80% relative risk reduction in peanut allergy at age 5 in the LEAP early-introduction arm is one of the largest preventable-disease effects experienced practitioners get to deliver in primary care.
Illustrative Scenario
A four-year-old patient with known peanut allergy and prior anaphylactic episode accidentally ingested a peanut-containing dessert at a birthday party. Within ten minutes the child developed generalized urticaria, facial and periorbital swelling, audible inspiratory stridor, and tachycardia with a measured systolic blood pressure that read low for age. The school nurse on scene administered the child’s prescribed EpiPen Jr (0.15 mg) intramuscularly to the mid-anterolateral thigh through clothing within four minutes of symptom onset and activated emergency medical services.
On ED arrival the child remained tachycardic and had a borderline blood pressure with persistent mild stridor. A second IM epinephrine dose (0.15 mg) was given at the 12-minute mark from initial dose, intravenous normal saline 20 mL/kg was infused, nebulized albuterol was added for residual wheeze, and intravenous methylprednisolone was given for ongoing urticaria. Symptoms resolved over the next 90 minutes. Given the severe initial presentation with two epinephrine doses, the patient was observed for 8 hours without biphasic recurrence. Discharge medications included two auto-injectors (one for home, one for school), a written anaphylaxis action plan, antihistamine for residual urticaria, and an outpatient pediatric allergy referral for component-resolved diagnostics and discussion of oral immunotherapy candidacy.
Takeaway: Rapid school-based IM epinephrine plus protocol-driven second-dose escalation plus a discharge package with two auto-injectors and a written action plan converts a potentially catastrophic event into a structured recovery. The decisive moment was the school nurse’s four-minute response.
Standing Protocol Adjustments
- Give IM epinephrine to the mid-anterolateral thigh (vastus lateralis) on any two-body-system anaphylaxis or known-allergen exposure with airway or hypotension — never deltoid, never subcutaneous, never wait for diphenhydramine to work.
- Weight-based dosing: 0.15 mg for 7.5–25 kg (0.1 mg for 7.5 to <15 kg where available), 0.3 mg for > 25 kg, and 0.01 mg/kg drawn up from 1 mg/mL below 7.5 kg; through clothing if needed; document site and time of every dose.
- Anticipate the second dose at 5–15 minutes if any persistent or worsening respiratory or cardiovascular feature; pair with IV fluid 20 mL/kg boluses; remember adjuncts (antihistamines, steroids, β-agonists) do not replace epinephrine.
- Discharge every anaphylaxis patient with two auto-injectors, a written action plan, antihistamine for residual urticaria, and an allergy referral; for high-risk infants (severe eczema, egg allergy), have the LEAP-aligned early peanut introduction conversation at the 4- to 6-month well-child visit.
- Anaphylaxis Emergency Management: Diagnosis, Epinephrine, and Discharge
- Anaphylaxis Clinical Guideline
- Stress Ulcer Prophylaxis in the ICU: Risk Stratification and Drug Selection
- Hyperammonemia in the ICU: Causes, Lactulose, Rifaximin, CRRT
- Sepsis and Septic Shock — Early Recognition and Evidence-Based Management
- Post-ICU Syndrome (PICS): Cognitive, Physical, Mental Health Recovery